Gentronix Announces LSG Agreement

Innovative biotechnology company Gentronix (Manchester, UK) is pleased to announce a new agreement with LSG Corporation (Tokyo, Japan).

The deal enables introduction of the GreenScreen® HC range of human cell-based genotoxicity assays across Japan, allowing scientists to accelerate the pace of drug discovery and development.

As a subsidiary of EPS Co, Ltd, one of the largest clinical research organisations in Japan, LSG was considered the ideal partner to promote the benefits of GreenScreen assays in this key market.

Steve Beasley, Commercial Director at Gentronix said “We are delighted to have signed this agency agreement with LSG Corporation. LSG’s experience and extensive contacts in the Japanese life sciences and toxicology sectors will help to further develop our customer base in this important market.”